Victory for Rothwell Figg Clients Pfizer and Synthon in Teva’s COPAXONE® Hatch-Waxman Patent Infringement Case

The United States District Court for the District of Delaware issued an opinion invalidating all four patents at issue in a recent victory for Rothwell Figg clients Pfizer and Synthon in Teva’s COPAXONE® Hatch-Waxman patent infringement case. Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Teva Neuroscience, Inc., and Yeda Research and Development Co., Ltd. alleged that Pfizer Inc., Synthon Pharmaceuticals Inc., Synthon B.V., and Synthon s.r.o. infringed U.S. Patent Nos. 8,232,250, 8,399,413, 8,969,302, and 9,155,776 relating to methods of treating relapsing-remitting forms of multiple sclerosis with a 40 mg/mL glatiramer acetate treatment regimen. After a seven day bench trial, the District of Delaware held that “[a]fter having considered the entire record in this case and the applicable law, the court concludes that all asserted claims of the patents-in-suit are invalid as obvious.”

The case is In re Copaxone 40 mg Consolidated Cases, civil action number 14-1171-GMS in the United States District Court for the District of Delaware.

Pfizer and Synthon were represented by E. Anthony Figg and Brett Postal of Rothwell Figg.